Pharma Focus America

Veneno Technologies, a Novel DRP Drug Discovery Company, has entered into a joint research agreement with Astellas Pharma Inc.

Tuesday, April 11, 2023

Veneno Technologies Co. Ltd. is pleased to announce that we have entered into a joint research agreement with Astellas Pharma Inc. ("Astellas")

Under the terms of the agreement, Veneno [https://veneno.jp/] will conduct a program to obtain functional peptides (DRPs) for G protein-coupled receptors (GPCRs) targeted by Astellas using our next-generation peptide discovery technology, the PERISS method (intra-periplasm secretion and selection). Work on this project is expected to begin during the 1st Quarter, 2023.

 

Source: prnewswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024